Autonomix Medical raises $2.6M via warrant inducement agreement

Autonomix Medical, Inc. (NASDAQ: AMIX) announced a warrant inducement agreement with an investor for the exercise of outstanding warrants originally issued on Nov. 19, 2025, according to a press release.

The investor agreed to exercise warrants to purchase 428,731 shares of common stock at a reduced exercise price of $6.00 per share. Gross proceeds are expected to be approximately $2.6 million before financial advisory fees and offering expenses. The transaction is expected to close on or about July 15, 2026, subject to customary closing conditions.

In exchange for the immediate cash exercise of the existing warrants, Autonomix agreed to issue two new series of unregistered warrants to the investor. The Series D-1 and Series D-2 warrants each cover 428,731 shares of common stock at an exercise price of $5.75 per share. Both warrant series are exercisable immediately upon issuance and expire five and a half years from the date of issuance. Autonomix said it will file a registration statement with the Securities and Exchange Commission to cover the resale of shares issuable upon exercise of the new warrants.

The new warrants are being issued in a private placement under an exemption from registration requirements of the Securities Act of 1933 and have not been registered with the SEC.

Maxim Group LLC served as warrant inducement agent and financial advisor for the transaction.

You May Also Be Interested In

• Energy Vault’s 100 MW AI Infrastructure Project in Sardinia Receives Italian Government Designation as Project of Pre-Eminent National Strategic Interest
• Profound Medical names Richard Fabian as president
• CleanCore Solutions rebrands as Zone Frontier, shifts to AI data centers